PortfolioRapha Capital Management Better than Eylea, as durable as gene therapy? Perceptive, Xontogeny boost ophthalmic startup’s shot for best of all worlds
PortfolioRapha Capital Management AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis
PortfolioRapha Capital Management Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer
PortfolioRapha Capital Management Rapha Capital Management Leads Series A Financing for FIZE Medical Inc.
PortfolioRapha Capital Management AsclepiX Therapeutics, Inc. Expands Leadership Team with Appointment of Industry Leader Theresa Heah, MD, MBA as Chief Medical Officer
PortfolioRapha Capital Management 3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
PortfolioRapha Capital Management 3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
